OICHARTS
8 AMThe 8 AM report →
PharmaMedium impactAfter close

Themis Medicare credit rating downgraded by CARE Ratings

Themis Medicare's credit rating was downgraded by CARE Ratings to BB+ from BBB-, citing deteriorating profitability. The company's operating income fell 15.34% to ₹344.58 crore in FY26, raising concerns over its financial stability.

after close1 source ↓machine-written, see hownot a recommendation

Limited disclosed
9 October 2026
facilities amount
₹77.39 crore
short-term facilities total
₹48.50 crore
income fell
15.34%
in FY26
₹344.58 crore

Themis Medicare Limited disclosed on 9 October 2026 that CARE Ratings Limited has downgraded its long-term bank facilities to CARE BB+; Stable from CARE BBB-; Negative. The downgrade reflects the company's deteriorating profitability and weaker debt coverage. Additionally, its short-term bank facilities were downgraded to CARE A4+ from CARE A3. The long-term bank facilities amount to ₹77.39 crore, while the short-term facilities total ₹48.50 crore.

The downgrade is significant as it indicates a decline in credit quality, which could impact Themis Medicare's ability to secure financing and manage its operational costs effectively. The company's consolidated total operating income fell by 15.34% to ₹344.58 crore in FY26 from ₹407.01 crore in FY25, highlighting ongoing financial challenges. Furthermore, the promoter's pledged shareholding increased to 43% as of 30 June 2026, up from previous levels, following a fund raise aimed at acquiring investments in GTBL. This increase in pledged shares may raise concerns among investors regarding the financial stability of the company.

Looking ahead, investors should monitor Themis Medicare's upcoming financial disclosures and any strategic initiatives aimed at improving profitability. The company's ability to stabilize its financial metrics will be crucial for regaining investor confidence and potentially reversing the downgrade.

Source: Kalkine India, 9 October 2026

Not investment advice. For informational purposes only.

This bulletin was generated by OI Charts' system from the sources listed here and from OI Charts market data, and was published without individual review. Read how bulletins are made or report an error. OI Charts is not a SEBI-registered investment adviser or research analyst. This is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 9 Oct 2026, 16:03 IST.

Sourcesnews.google.com

The market after the news

GUJTHEM closed +2.3% on the day of the news, from ₹363.50 to ₹371.75; Nifty −0.7% over the same session.

Bulletin at 16:03 IST on 9 Oct 2026. Every change is measured from ₹363.50, the last close before it, on 9 Oct. Nifty 50 is measured over the same sessions.

  • GUJTHEM close ₹
  • Nifty 50, rebased to the close before the news
  • close before the news
  • above it
  • below it
GUJTHEM closes around the bulletin against the close before the news, with Nifty 50 rebased to it290.95363.50436.05axis spans 50%before the news · 9 Oct363.50Nifty 50GUJTHEMbulletinD0+15 Oct9 Oct14 OctReference close ₹363.50. 8 sessions from 5 Oct to 14 Oct; the price axis spans 50 percent.
price axis fixed at 4 × the 14-session true range around the close before the news · values printed at each marked session
Closes after the news against the close before it, with Nifty 50 over the same span
SessionClose ₹Change %Nifty %
Before9 Oct₹363.50basebase
On the day12 Oct₹371.75▲ +2.3%▼ −0.7%+3.0 pp difference
+1 session13 Oct₹373.00▲ +2.6%▲ +0.9%+1.7 pp difference
+3 sessionsnot reached yet———
+5 sessionsnot reached yet———
Gap at the open, % · ₹
▲ +1.2%+4.36 on 12 Oct
Day's range, % · ₹
3.2%≈ 12 high to low
Volume on the day
0.68×the 20-session average
Futures OI on the day
—
Futures OI open, lots
—
Futures premium, ₹
—
Puts per call, by OI
—
Max pain
—

Source NSE UDiFF bhavcopy · GUJTHEM on the desk →

Sector · PharmaAll Pharma bulletins →